Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Cue Biopharma

Healthcare US CUE

28.24USD
-1.4(4.72%)

Last update at 2026-06-05T15:32:00Z

Day Range

26.7528.40
LowHigh

52 Week Range

0.171.03
LowHigh

Fundamentals

  • Previous Close 29.64
  • Market Cap65.43M
  • Volume30282
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-25.56300M
  • Revenue TTM27.47M
  • Revenue Per Share TTM0.29
  • Gross Profit TTM -7.37700M
  • Diluted EPS TTM-0.28

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -26.10200M -40.67400M -50.73300M -53.01038M -43.66618M
Minority interest - - - - -
Net income -26.60200M -40.67400M -50.73300M -52.79595M -44.16118M
Selling general administrative 16.24M 14.59M 16.68M 16.17M 17.31M
Selling and marketing expenses - - 2.91M - -
Gross profit 23.99M 9.29M -32.60700M 1.25M 14.94M
Reconciled depreciation 3.48M 2.35M 3.44M 1.81M -1.77798M
Ebit -26.52100M -39.87800M -49.48800M -53.22481M -41.93409M
Ebitda -23.04100M -37.52800M -46.05200M -50.76714M -43.71207M
Depreciation and amortization 3.48M 2.35M 3.44M 2.46M -1.77798M
Non operating income net other - - - - -
Operating income -26.55200M -41.50000M -52.14900M -53.22481M -43.71207M
Other operating expenses 53.99M 50.79M 57.64M 54.75M 58.65M
Interest expense 0.36M 0.80M 1.25M 0.71M 1.73M
Tax provision 0.50M 0.00000M - 0.00000M 0.49M
Interest income 0.81M 1.62M 2.66M 0.93M 0.05M
Net interest income 0.45M 0.83M 1.42M 0.21M 0.05M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.50M -40.67400M 3.27M -0.21443M 0.49M
Total revenue 27.47M 9.29M 5.49M 1.25M 14.94M
Total operating expenses 50.51M 50.79M 19.54M 54.75M 58.65M
Cost of revenue 3.48M 2.35M 38.10M - -
Total other income expense net 0.42M 0.83M 1.42M 0.21M 0.05M
Discontinued operations - - - - -
Net income from continuing ops -26.60200M -40.67400M -50.73300M -53.01038M -44.16118M
Net income applicable to common shares - - - -53.01038M -44.16118M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 42.21M 32.19M 61.53M 91.28M 83.40M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.40M 0.81M 1.24M 0.84M 0.95M
Total liab 15.78M 14.69M 24.45M 25.60M 17.91M
Total stockholder equity 26.43M 17.50M 37.09M 65.68M 65.49M
Deferred long term liab - - - - -
Other current liab 7.63M 2.99M 4.14M 3.55M 4.62M
Common stock 0.10M 0.06M 0.05M 0.04M 0.03M
Capital stock 0.10M 0.06M 0.05M 0.04M 0.03M
Retained earnings -368.46600M -341.86400M -301.19000M -250.45660M -197.44621M
Other liab - - - - -
Good will - - - - -
Other assets - - - 3.39M 3.01M
Cash 27.14M 22.46M 48.51M 51.61M 64.37M
Cash and equivalents - - - - -
Total current liabilities 13.49M 13.69M 17.08M 11.55M 12.79M
Current deferred revenue - 0.09M 2.11M - 0.65M
Net debt -22.93900M -13.58300M -33.81900M -32.29856M -54.31795M
Short term debt 1.91M 7.87M 7.33M 5.26M 4.93M
Short long term debt - 4.33M 3.96M 1.96M -
Short long term debt total 4.20M 8.88M 14.70M 19.32M 10.05M
Other stockholder equity 394.80M 359.30M 338.23M 316.19M 262.91M
Property plant equipment - - - 1.50M 2.11M
Total current assets 36.98M 25.14M 51.45M 77.19M 68.47M
Long term investments - - - - -
Net tangible assets - - - 65.68M 65.49M
Short term investments - 0.93M 0.00000M 24.67M 0.00000M
Net receivables 7.45M 0.94M 1.70M 0.06M 3.14M
Long term debt - - 4.20M 8.03M -
Inventory - - 0.00000M - -
Accounts payable 3.95M 2.82M 3.50M 2.73M 2.59M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -0.09587M -
Additional paid in capital - - - - -
Common stock total equity - - - 0.04M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -250.45660M -197.44621M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.76M 2.21M 2.81M 3.39M 3.01M
Deferred long term asset charges - - - - -
Non current assets total 5.23M 7.05M 10.08M 14.10M 14.93M
Capital lease obligations 4.20M 4.54M 6.53M 9.32M 10.05M
Long term debt total - - - 8.03M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.21M 0.03M 25.00M -29.44534M 10.00M
Change to liabilities - - - -0.98747M 2.35M
Total cashflows from investing activities 0.07M 0.03M 25.00M -24.60988M 9.11M
Net borrowings -4.50000M -3.99900M -2.00000M 14.56M 10.00M
Total cash from financing activities 26.29M 10.24M 11.86M 53.66M 19.23M
Change to operating activities - - - -2.16677M -3.18281M
Net income -26.60200M -40.67400M -50.73300M -53.01038M -44.16118M
Change in cash 4.68M -26.05400M -3.09900M -12.75670M -10.49533M
Begin period cash flow 22.61M 48.66M 51.76M 64.52M 75.02M
End period cash flow 27.29M 22.61M 48.66M 51.76M 64.52M
Total cash from operating activities -21.68700M -36.32900M -39.96100M -41.80595M -38.83717M
Issuance of capital stock 30.79M 14.22M 13.39M 39.30M 17.38M
Depreciation 0.96M 2.35M 3.44M 1.81M -1.77798M
Other cashflows from investing activities 0.21M 0.10M 0.00200M 5.01M 10.02M
Dividends paid - - - - -
Change to inventory - - - - 4.79M
Change to account receivables -6.50000M 0.75M -1.64100M 3.09M -1.72504M
Sale purchase of stock - - - 22.50M 19.23M
Other cashflows from financing activities 26.29M 0.02M 0.47M 14.50M 1.85M
Change to netincome - - - 9.50M 11.49M
Capital expenditures 0.18M 0.07M 0.00000M 0.17M 0.91M
Change receivables - - - 3.09M -1.72504M
Cash flows other operating - - - -1.02563M -1.97992M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -12.75670M -10.49533M
Change in working capital -3.29500M -4.92500M -0.93400M 0.36M -4.38746M
Stock based compensation 4.74M 6.85M 8.18M 9.50M 11.52M
Other non cash items 2.51M 0.07M 0.09M -0.45378M -0.02613M
Free cash flow -21.86400M -36.39500M -39.96100M -41.97670M -39.75021M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CUE
Cue Biopharma		 -1.4 4.72% 28.24 - - 2.38 3.14 2.19 -1.7598
NVO
Novo Nordisk A/S		 -0.015 0.03% 43.73 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.0037 0.0084% 44.19 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 7.17 1.62% 448.90 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 7.53 1.20% 636.26 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Cue Biopharma

40 Guest Street, Boston, MA, United States, 02135

Key Executives

Name Title Year Born
Mr. Daniel R. Passeri J.D., M.Sc., MSc. CEO & Director 1961
Dr. Anish Suri Ph.D. Pres & Chief Scientific Officer 1974
Ms. Kerri-Ann Millar Chief Financial Officer 1970
Dr. Ronald D. Seidel III, Ph.D. Co-Founder 1976
Dr. Rodolfo J. Chaparro Co-Founder & Sr. Advisor 1973
Dr. Steven C. Almo Co-Founder and Chairman of Scientific & Clinical Advisory Board 1961
George B. Zavoico Ph.D. VP of Investor Relations & Corp. Devel. NA
Mr. Colin G. Sandercock J.D., MSE Sr. VP, Gen. Counsel & Sec. 1957
Dr. Kenneth J. Pienta M.D. Acting Chief Medical Officer 1960
Dr. Matteo Levisetti M.D. Sr. VP of Clinical Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.